Literature DB >> 19200028

The potential of modulating small RNA activity in vivo.

Alain van Mil1, Pieter A Doevendans, Joost P G Sluijter.   

Abstract

Small RNAs have shown to be ubiquitous, useful, post-transcriptional gene silencers in a diverse array of living organisms. As a result of homologous sequence interactions, these small RNAs repress gene expression. Through a process called RNA interference (RNAi), double strand RNA molecules are processed by an enzyme called Dicer, which cleaves RNA duplexes into 21-23 base pair oligomers. Depending on their end-point functions, these oligomers are named differently, the two most common being small interfering RNAs (siRNAs) and microRNAs (miRNAs). These small RNAs are the effector molecules for inducing RNAi, leading to post-transcriptional gene silencing by guiding the RNAi-induced silencing complex (RISC) to the target mRNA. By exploiting these small RNAs, it is possible to regulate the expression of genes related to human disease. The knockdown of such target genes can be achieved by transfecting cells with synthetically engineered small RNAs or small RNA expressing vectors. Within recent years, studies have also shown the important role of miRNAs in different diseases. By using several chemically engineered anti-miRNA oligonucleotides, disease related miRNAs can be specifically and effectively silenced. Since RNAi has developed into an everyday method for in vitro knockdown of any target gene of interest, the next step is to further explore its potential in vivo and the unique opportunities it holds for the development of novel therapeutic strategies. This review explores the various applications of small RNA technology in in vivo studies, and its potential for silencing genes associated with various human diseases. We describe the latest development in small RNA technology for both gene knockdown, and the inhibition of translational silencing in animal studies. A variety of small RNA formulations and modifications will be reviewed for their improvement on stability and half-life, their safety and off-target effects, and their efficiency and specificity of gene silencing.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19200028     DOI: 10.2174/138955709787316029

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  8 in total

1.  Short RNA duplexes guide sequence-dependent cleavage by human Dicer.

Authors:  Lucien Bergeron; Jean-Pierre Perreault; Sherif Abou Elela
Journal:  RNA       Date:  2010-10-25       Impact factor: 4.942

2.  MicroRNA-338 and microRNA-21 co-transfection for the treatment of rat sciatic nerve injury.

Authors:  Jianyong Wang; Aikeremujiang Muheremu; Ming Zhang; Kai Gong; Chuyi Huang; Yuchen Ji; Yujun Wei; Qiang Ao
Journal:  Neurol Sci       Date:  2016-02-24       Impact factor: 3.307

3.  Inhibition of ATIR by shRNA prevents collagen synthesis in hepatic stellate cells.

Authors:  Peihong Dong; Fujun Yu; Xufei Fan; Zhuo Lin; Yongping Chen; Ji Li
Journal:  Mol Cell Biochem       Date:  2010-08-12       Impact factor: 3.396

Review 4.  In vitro 3D model and miRNA drug delivery to target calcific aortic valve disease.

Authors:  Casper F T van der Ven; Pin-Jou Wu; Mark W Tibbitt; Alain van Mil; Joost P G Sluijter; Robert Langer; Elena Aikawa
Journal:  Clin Sci (Lond)       Date:  2017-02-01       Impact factor: 6.124

Review 5.  Sequence-non-specific effects of RNA interference triggers and microRNA regulators.

Authors:  Marta Olejniczak; Paulina Galka; Wlodzimierz J Krzyzosiak
Journal:  Nucleic Acids Res       Date:  2009-10-20       Impact factor: 16.971

6.  The pathophysiological basis of pharmacological interventions in CAVD.

Authors:  P W Riem Vis; J-W van Rijswijk; S A J Chamuleau; A Vink; L A van Herwerden; J Kluin
Journal:  Neth Heart J       Date:  2012-06       Impact factor: 2.380

7.  Controlled delivery of gold nanoparticle-coupled miRNA therapeutics via an injectable self-healing hydrogel.

Authors:  Casper F T van der Ven; Mark W Tibbitt; João Conde; Alain van Mil; Jesper Hjortnaes; Pieter A Doevendans; Joost P G Sluijter; Elena Aikawa; Robert S Langer
Journal:  Nanoscale       Date:  2021-12-16       Impact factor: 7.790

Review 8.  Encapsulation of miRNA and siRNA into Nanomaterials for Cancer Therapeutics.

Authors:  Mina Zare; Rakesh Pemmada; Maya Madhavan; Aswathy Shailaja; Seeram Ramakrishna; Sumodan Padikkala Kandiyil; James M Donahue; Vinoy Thomas
Journal:  Pharmaceutics       Date:  2022-08-03       Impact factor: 6.525

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.